For research use only. Not for therapeutic Use.
H-Asn(glcnac-beta-D)-OH is an endogenous metabolite present in Urine that can be used for the research of NGLY1-CDDG[1][2].
Endogenous metabolites is defined as those that are annotated by Kyoto Encyclopedia of Genes and Genomes as substrates or products of the ~1900 metabolic enzymes encoded in our genome. It is clear in the body of literature that there are documented toxic properties for many of these metabolites[1].
| Catalog Number | I042450 |
| CAS Number | 2776-93-4 |
| Synonyms | (2S)-4-[[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-2-amino-4-oxobutanoic acid |
| Molecular Formula | C12H21N3O8 |
| Purity | ≥95% |
| InChI | InChI=1S/C12H21N3O8/c1-4(17)14-8-10(20)9(19)6(3-16)23-11(8)15-7(18)2-5(13)12(21)22/h5-6,8-11,16,19-20H,2-3,13H2,1H3,(H,14,17)(H,15,18)(H,21,22)/t5-,6+,8+,9+,10+,11+/m0/s1 |
| InChIKey | YTTRPBWEMMPYSW-HRRFRDKFSA-N |
| SMILES | CC(=O)NC1C(C(C(OC1NC(=O)CC(C(=O)O)N)CO)O)O |
| Reference | [1]. Lee N, et al. Endogenous toxic metabolites and implications in cancer therapy. Oncogene. 2020 Aug;39(35):5709-5720. [2]. Haijes HA, et al. Aspartylglycosamine is a biomarker for NGLY1-CDDG, a congenital disorder of deglycosylation. Mol Genet Metab. 2019 Aug;127(4):368-372. |
